{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:38:29Z","timestamp":1771472309224,"version":"3.50.1"},"reference-count":35,"publisher":"Impact Journals, LLC","issue":"62","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,12,1]]},"DOI":"10.18632\/oncotarget.21362","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T01:21:45Z","timestamp":1506648105000},"page":"105093-105102","source":"Crossref","is-referenced-by-count":10,"title":["Intrapleural targeted therapies (anti-VEGF and anti-EGFR) in the model of malignant pleural effusion"],"prefix":"10.18632","volume":"8","author":[{"given":"Milena Marques Pagliarelli","family":"Acencio","sequence":"first","affiliation":[{"name":"Laboratorio de Pleura \/ LIM09 - Divisao de Pneumologia, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Puka","sequence":"additional","affiliation":[{"name":"Laboratorio de Pleura \/ LIM09 - Divisao de Pneumologia, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa Ad\u00e9lia","family":"Alvarenga","sequence":"additional","affiliation":[{"name":"Laboratorio de Pleura \/ LIM09 - Divisao de Pneumologia, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Martins","sequence":"additional","affiliation":[{"name":"Departmento de Patologia, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Lombardi Peres","family":"de Carvalho","sequence":"additional","affiliation":[{"name":"Laboratorio de Genetica e Cardiologia Molecular, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evaldo","family":"Marchi","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina de Jundiai, Jundiai SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera Luiza","family":"Capelozzi","sequence":"additional","affiliation":[{"name":"Departmento de Patologia, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisete Ribeiro","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Laboratorio de Pleura \/ LIM09 - Divisao de Pneumologia, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,9,28]]},"reference":[{"key":"1","first-page":"177","article-title":"Malignant pleural effusion","volume":"22","author":"Sahn","year":"2002","journal-title":"Eur Respir Mon"},{"key":"2","first-page":"32","article-title":"Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010","volume":"65","author":"Ali","year":"2010","journal-title":"Thorax"},{"key":"3","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"The Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2011.04.001","article-title":"Targeted therapies for advanced non-small cell lung cancer: current status and future implications","volume":"38","author":"Provencio","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00063198-200207000-00009","article-title":"Vascular endothelial growth factor: the key mediator in pleural effusion formation","volume":"8","author":"Gary","year":"2002","journal-title":"Curr Opin Pulm Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/pr.56.4.3","article-title":"Vascular Endothelial Growth Factor and Angiogenesis","volume":"56","author":"de Bruijn","year":"2004","journal-title":"Pharmacol Rev"},{"key":"7","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.2174\/13816128113199990343","article-title":"New molecular targets in the treatment of NSCLC","volume":"19","author":"Gridelli","year":"2013","journal-title":"Curr Pharm Des"},{"key":"8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-010-9201-z","article-title":"Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy","volume":"29","author":"Gazdar","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"9","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-06-3043","article-title":"KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"13","author":"Wistuba","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"key":"11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.lungcan.2011.11.013","article-title":"The role of molecular analyses in the era of personalized therapy for advanced NSCLC","volume":"76","author":"Silvestri","year":"2012","journal-title":"Lung Cancer"},{"key":"12","first-page":"1462","article-title":"Panel Members. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up","volume":"25","author":"Felip","journal-title":"Ann Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ctrv.2013.07.002","article-title":"ALK inhibitors in the treatment of advanced NSCLC","volume":"40","author":"Ciardiello","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cllc.2015.02.006","article-title":"Treatment of unfit patients with advanced non-small-cell lung cancer: definition criteria according an expert panel","volume":"16","author":"Gridelli","year":"2015","journal-title":"Clinical Lung Cancer"},{"key":"15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1165\/rcmb.2005-0130OC","article-title":"Nuclear factor-kappa B affects tumor progression in a mouse model of malignant pleural effusion","volume":"34","author":"Blackwell","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"16","first-page":"1","article-title":"Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study","volume":"9","author":"Stathopoulos","year":"2010","journal-title":"Molecular Cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/resp.12151","article-title":"Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion","volume":"19","author":"Kalomenidis","year":"2014","journal-title":"Respirology"},{"key":"18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MCP.0b013e32832af07c","article-title":"Animal models of malignant pleural effusion","volume":"15","author":"Kalomenidis","year":"2009","journal-title":"Curr Opin Pulm Med"},{"key":"19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12967-015-0662-2","article-title":"A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells","volume":"13","author":"Teixeira","year":"2015","journal-title":"J Transl Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti\u2013EGFR Agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol Cancer Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1440-1843.2009.01628.x","article-title":"Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion","volume":"14","author":"Teixeira","year":"2009","journal-title":"Respirology"},{"key":"22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3181\/0901-MR-12","article-title":"The epidermal growth factor receptor: a link between inflammation and liver cancer","volume":"234","author":"Avila","year":"2009","journal-title":"Exp Biol Med"},{"key":"23","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1200\/jco.2005.23.16_suppl.3536","article-title":"Molecular determinants of cetuximab efficacy","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ijrobp.2003.09.091","article-title":"Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies","volume":"58","author":"Kerbel","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1158\/1078-0432.397.11.1","article-title":"Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor","volume":"11","author":"Ellis","year":"2005","journal-title":"Clin Cancer Res"},{"key":"26","first-page":"5090","article-title":"Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies: a role for altered tumor angiogenesis","volume":"61","author":"Kerbel","year":"2001","journal-title":"Cancer Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.2147\/OTT.S97907","article-title":"Correlations between EGFRgene polymorphisms and pleural metastasis of lung adenocarcinoma","volume":"9","author":"Wang","year":"2016","journal-title":"OncoTargets and Therapy"},{"key":"28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cllc.2012.09.007","article-title":"KRAS Mutations in Lung Cancer","volume":"14","author":"Rosell","year":"2013","journal-title":"Clinical Lung Cancer"},{"key":"29","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","article-title":"Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications","volume":"64","author":"Mitsudomi","year":"2004","journal-title":"Cancer Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-04-2618","article-title":"Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas","volume":"11","author":"Sanchez-Ronco","year":"2005","journal-title":"Clin Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1440-1827.2010.02580.x","article-title":"KRAS gene mutations in lung cancer: particulars established and issues unresolved","volume":"60","author":"Kitamura","year":"2010","journal-title":"Pathol Int"},{"key":"32","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1200\/JCO.2009.27.4365","article-title":"Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?","volume":"28","author":"Socinski","year":"2010","journal-title":"J Clin Oncol"},{"key":"33","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.lungcan.2009.11.020","article-title":"KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies","volume":"69","author":"Chen","year":"2010","journal-title":"Lung Cancer"},{"key":"34","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/bioinformatics\/bts199","article-title":"Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data","volume":"28","author":"Mentjies","year":"2012","journal-title":"Bioinformatics"},{"key":"35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of Relative Gene Expression Data Using Real Time Quantitative PCR and the 22\u2212\u0394\u0394CT Method","volume":"25","author":"Schmittgen","year":"2001","journal-title":"Methods"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T17:25:22Z","timestamp":1659547522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,28]]},"references-count":35,"journal-issue":{"issue":"62","published-print":{"date-parts":[[2017,12,1]]}},"alternative-id":["21362","29285236"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.21362","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,28]]}}}